Oxbryta (Voxelotor) Withdrawal and the Claims That Followed

Oxbryta (voxelotor) was an oral, once-daily tablet for sickle cell disease, approved by the FDA under its accelerated approval pathway in 2019 for patients 12 and older and extended in 2021 to patients 4 and older. Pfizer voluntarily withdrew all lots from every market where the drug was approved on September 25, 2024 and ended its trials and access programs, citing post-marketing data showing an imbalance in vaso-occlusive crises and fatal events. The FDA alerted patients and prescribers the next day. Lawsuits followed, but they are not consolidated in a federal multidistrict proceeding: injury cases and a consumer economic-loss class action have been coordinated before one judge in San Francisco, and one federal court has already dismissed a patient’s claims on preemption grounds.

What Oxbryta was, and what the FDA and Pfizer said in 2024

Oxbryta was a hemoglobin S polymerization inhibitor taken once daily to reduce the sickling that causes vaso-occlusive crises. The FDA granted accelerated approval in 2019 for adults and patients 12 and older based on an increase in hemoglobin, and in December 2021 extended the approved use to patients 4 and older (FDA alert; Pfizer health care provider letter). Accelerated approval rests on an intermediate endpoint reasonably likely to predict clinical benefit and generally requires post-marketing studies to verify it (FDA alert).

On September 25, 2024, Pfizer announced that it was voluntarily withdrawing all lots of Oxbryta in all markets where it was approved and discontinuing all active voxelotor clinical trials and expanded access programs, saying the decision rested on the totality of clinical data indicating that the overall benefit no longer outweighed the risk, and that the data suggested an imbalance in vaso-occlusive crises and fatal events requiring further assessment (Pfizer press release).

The FDA’s September 26, 2024 alert repeated the manufacturer’s announcement and added detail: in post-marketing trials, Pfizer reported a higher rate of vaso-occlusive crisis in patients receiving Oxbryta than in those receiving placebo, and more deaths in the treatment group; a higher rate of crisis was also seen in two real-world registry studies. The agency said it was reviewing the data and would report further findings.

What is established, and what is only alleged

Established: the approval history; the manufacturer’s September 25, 2024 announcement of a worldwide voluntary withdrawal; the FDA’s September 26, 2024 alert describing the post-marketing signals and confirming its own review; and the existence of federal and state litigation over the drug, including a July 27, 2026 opinion dismissing one patient’s claims.

Alleged, and not decided: that Oxbryta caused any individual’s injuries, which in the cases reviewed include vaso-occlusive crises, strokes and a death; that the defendants knew or should have known of a greater risk earlier than they disclosed it; and that the labeling was inadequate. Where a court has examined those claims, it did so at the pleading stage, assuming the complaint’s factual allegations to be true.

Where the claims stand procedurally

There is no Oxbryta multidistrict litigation. Oxbryta and voxelotor do not appear in the Judicial Panel on Multidistrict Litigation’s September 1, 2026 report of pending MDL dockets, which lists active transferred proceedings by district and docket number. The federal Oxbryta cases have instead been coordinated as related cases in the Northern District of California before Judge Trina L. Thompson.

A joint case management statement filed August 21, 2025 in Allen v. Global Blood Therapeutics, Inc., No. 3:24-cv-07786 (N.D. Cal.), identifies four related federal cases: Allen (complaint filed November 7, 2024), Jolly, No. 3:24-cv-09345 (a putative consumer class action, with a motion to dismiss filed April 23, 2025), Frazier, No. 3:25-cv-04027 (complaint filed May 8, 2025) and Ford, No. 3:25-cv-04229 (complaint filed May 16, 2025). It also lists fourteen state-court product-liability cases, nine in California.

Preemption is the central contested issue. In Cosey v. Global Blood Therapeutics, Inc., No. 1:25-cv-09400, the Northern District of Illinois granted the defendants’ motion to dismiss on July 27, 2026, holding a design defect claim preempted because a manufacturer cannot unilaterally change a drug’s composition without FDA approval, and dismissing it with prejudice. The failure-to-warn, negligence and warranty claims were dismissed without prejudice because the complaint did not identify newly acquired information that could have supported a unilateral label change before the withdrawal.

On the consumer track, Mealey’s reported on September 17, 2026 that Pfizer and Global Blood Therapeutics had agreed to fund up to $750,000 in reimbursements for out-of-pocket Oxbryta purchases, in an unopposed motion for preliminary approval of a class settlement of the economic-loss claims (secondary reporting; no court-approved claims process was located).

Key dates

• 2019: FDA grants accelerated approval for adults and patients 12 and older (FDA alert).
• December 2021: the approval is extended to patients 4 and older (FDA health care provider letter).
• September 25, 2024: Pfizer announces the worldwide voluntary withdrawal and ends its Oxbryta trials and access programs (Pfizer press release).
• September 26, 2024: FDA alerts patients and prescribers and describes its safety review (FDA alert).
• November 7, 2024: complaint filed in Allen, No. 3:24-cv-07786 (joint case management statement).
• July 27, 2026: motion to dismiss granted in Cosey, No. 1:25-cv-09400 (court opinion).
• September 1, 2026: the JPML’s pending-docket report lists no Oxbryta proceeding.

What this does not establish

Nothing in the record reviewed here shows a court or agency finding that Oxbryta caused any individual’s injury or death. The withdrawal was a manufacturer decision, and a market withdrawal is not an adjudication of causation: the FDA’s alert repeated the company’s stated basis and described its own review. The judicial ruling examined here was decided on a motion to dismiss, before evidence was tested, and turned on preemption and pleading sufficiency, not on whether the drug injured the plaintiff.

There is also no approved settlement of the injury claims in the sources reviewed: the proposed class resolution reported by legal press concerns reimbursements for out-of-pocket purchases, a separate economic-loss theory, and awaited preliminary approval. A motion for preliminary approval is not a court-approved settlement with a published claims process, and the absence of an Oxbryta MDL from the Panel’s September 2026 report describes the docket as of that date only.

Frequently asked questions

Is there an Oxbryta MDL?

No Oxbryta multidistrict proceeding appears in the JPML’s September 1, 2026 report of pending MDL dockets; federal claims have instead been coordinated as related cases in the Northern District of California. A background guide to MDLs and class actions explains that difference.

Was Oxbryta recalled?

Pfizer announced a voluntary withdrawal of all lots from all markets where the drug was approved on September 25, 2024, and sent a letter to health care providers telling prescribers that patients should no longer receive the drug.

Why did a court dismiss one Oxbryta lawsuit?

In Cosey, the Northern District of Illinois granted the defendants’ motion to dismiss on July 27, 2026, holding a design defect claim preempted because a manufacturer cannot change a drug’s formulation without FDA approval, and dismissing the warning claims without prejudice for failure to identify newly acquired information supporting a unilateral label change. It is one ruling in one case, not a decision on whether Oxbryta caused injuries.

Do the Oxbryta cases involve a class action settlement I can join?

The proposed resolution reported by legal press concerns economic-loss claims by purchasers, not personal injury claims, and was reported as a motion for preliminary approval, not an approved settlement; no court-approved claims process was located. The pharmaceutical lawsuits section covers related litigation, including Depo-Provera meningioma claims and the Philips CPAP recall litigation.

Sources

1. U.S. Food and Drug Administration - “FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns” (link, accessed 2026-10-13)
2. Pfizer Inc. - “Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA (voxelotor) From Worldwide Markets” (link, accessed 2026-10-13)
3. Pfizer Inc. - “Pfizer Voluntarily Withdraws OXBRYTA (voxelotor) from the Market: Dear Health Care Provider letter” (link, accessed 2026-10-13)
4. U.S. District Court for the Northern District of California (filed document) - “Joint Case Management Statement, Allen v. Global Blood Therapeutics, Inc., No. 3:24-cv-07786 (N.D. Cal.)” (link, accessed 2026-10-13)
5. U.S. District Court for the Northern District of Illinois (opinion text via Midpage) - “Cosey v. Global Blood Therapeutics, Inc., No. 1:25-cv-09400, Memorandum Opinion and Order (N.D. Ill. July 27, 2026)” (link, accessed 2026-10-13)
6. U.S. Judicial Panel on Multidistrict Litigation - “MDL Statistics Report: Distribution of Pending MDL Dockets by Actions Pending, September 1, 2026” (link, accessed 2026-10-13)
7. Mealey’s (LexisNexis) - “Pfizer, GBT Agree To Pay Up To $750,000 To Settle Oxbryta Economic Loss Claims” (link, accessed 2026-10-13)

CollectiveClaim.us publishes general legal information. This article is not legal advice and does not create an attorney–client relationship. Court records and agency actions change; verify current status with the court or agency before relying on it.